Home » Healthcare » Pharmaceuticals » Mitotane Drug Market

Mitotane Drug Market By Formulation (Oral Tablets/Capsules, Injectable Formulations) By Indication (Adrenal Cortical Carcinoma (ACC), Cushing’s Syndrome) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Market Insights

The global demand for mitotane drug was valued at USD 17.5 Million in 2022 and is expected to reach USD 25.46 Million in 2030, growing at a CAGR of 4.8% between 2023 and 2030.
The oral tablets/capsules segment is the market leader by formulation, accounting for more than 65% of total value in 2022, while the injectable formulations segment is anticipated to grow rapidly throughout the projection period.
The Cushing’s syndrome indication category is expected to expand quickly in the projected period, while the adrenal cortical carcinoma (ACC) segment has the greatest market share in 2022.
The hospital pharmacies distribution channel dominates the global need for mitotane drugs, accounting for more than 60% in 2022 and is predicted to expand at a high CAGR.
The adjuvant therapy category dominated the market with 58% of the total revenue share by treatment phase. In contrast, the advanced or metastatic disease category will expand fastest over the projected time frame.
The pediatric category dominated the global market with 66% of the total revenue share by patient age group segment.
North America is driving the expansion of the mitotane drug industry, accounting for more than one-third of the market in 2022, while Asia Pacific and Europe account for just under 54% of the market in 2022. In 2022, Europe held more than 20% of the market.
Mitotane, also known as Lysodren, is primarily used in the treatment of adrenocortical carcinoma (ACC), a rare but aggressive cancer affecting the adrenal glands.
Although the frequency of ACC is low, the need for effective treatment choices for patients identified with this condition drives the demand for mitotane drugs.
As per the American Cancer Society, around 1,500 new cases of adrenal cancer are detected in the United States each year. This rising prevalence is expected to increase the demand for mitotane.
Mitotane is a successful treatment option for advanced adrenal cancer. Thus, patients and healthcare professionals are becoming increasingly dependent on this drug. Governments worldwide are raising healthcare spending in order to offer patients better treatment alternatives.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Executive Summary

Market Definition

The mitotane drug market refers to the segment of the pharmaceutical industry focused on the production, distribution, and sales of medications containing mitotane as the active pharmaceutical ingredient (API). Mitotane is primarily used in the treatment of adrenal cancer, a rare form of cancer that affects the adrenal glands. This market encompasses various aspects, including research and development, manufacturing, regulatory approvals, marketing, and distribution of mitotane-based drugs. It is characterized by its connection to the oncology and rare disease therapeutics sectors, with a focus on providing effective treatment options for patients diagnosed with adrenal cancer and exploring potential applications in related medical fields.

Market Overview

The global mitotane drug market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 4.8% between 2023 and 2030. The market was valued at USD 17.5 million in 2022 and is expected to reach USD 25.46 million in 2030.

Mitotane is mainly utilized for the treatment of adrenal cancer, and the demand for the drug is increasing as the disease spreads. The market for mitotane drugs is expected to grow steadily over the coming years as a result of increased awareness and diagnosis of adrenal cancer. Mitotane controls the amount of hormone generated by the adrenal gland. The drug acts by killing the adrenal gland cells that produce these hormones. Mitotane is also occasionally used to treat Cushing’s syndrome, a hormonal disease caused by chronic exposure to excessive levels of cortisol.

Mitotane manufacturers are able to diversify their product offerings into similar markets, such as those for oncology treatments or other endocrine therapies. Manufacturers will also be able to engage in research & development initiatives to improve the effectiveness and safety of mitotane as well as discover new applications for the medication. The companies are further working together to sell and market mitotane. Such developments are expected to boost market expansion in neglected areas and meet treatment demand.

Segmentation by Formulation

The injectable formulations segment will exhibit the highest CAGR in the projected period due to their convenience and effectiveness, especially in hospital settings where precise dosing is crucial.
The oral tablets/capsules segment currently leads the market share, holding over 65% in 2022, and is widely preferred for outpatient treatments and long-term use. Their ease of administration makes them the primary choice for patients.

Segmentation by Indication

The Cushing’s syndrome segment is expected to post the highest CAGR in the forecasted period. Mitotane’s role in treating Cushing’s syndrome is gaining wider prominence owing to its efficacy in managing excess cortisol production.
The adrenal cortical carcinoma (ACC) segment dominated the market with a principal revenue share of 54% in 2022. ACC is the primary indication for mitotane, making it the dominant category. The higher market share reflects the drug’s critical role in cancer treatment.

Segmentation by Distribution Channel

Hospital pharmacies are a dominant distribution channel category, accounting for more than 60% of the global demand for mitotane drugs in 2022 and is expected to grow at a high CAGR. The hospital pharmacy segment is critical in the distribution and dispensing of mitotane, a medicine principally used for managing adrenocortical cancer.
The retail pharmacies segment addresses the remaining need for mitotane drugs. Retail pharmacies serve as accessible points for patients to obtain mitotane for ongoing treatment and as a resource for prescription management.

Segmentation by Treatment Phase

Emerging as the leader in the treatment phase, the adjuvant therapy category captured a substantial 58% share in 2022. Adjuvant therapy with mitotane plays a vital role in preventing cancer recurrence after surgery. Its significant market share highlights its significance in long-term cancer management.
The segment addressing advanced or metastatic disease is expected to grow rapidly as more patients require mitotane for advanced cancer stages.

Segmentation by Patient Age Group

The adult segment is projected to exhibit substantial growth, reflecting the increasing use of mitotane in adult populations for various indications, including cancer and hormonal disorders.
The pediatric segment currently leads the market share, holding over 66% in 2022. Mitotane’s utilization in pediatric patients is significant, particularly for rare conditions. Its current market share emphasizes its importance in treating younger patients with specific medical needs.

Segmentation by Region

North America stands out as a highly profitable region for mitotane drug manufacturers and healthcare providers, holding over one-third of market share in 2022. Its advanced healthcare infrastructure and research capabilities contribute to its prominence in the market.
Asia Pacific and Europe collectively account for just under 54% share in 2022. Europe, with over 20% share in the same year, reflects a strong market presence.
The rest of the world, including Latin America, the Middle East, and Africa, contributes to the remaining demand for mitotane drugs. Emerging healthcare markets in these regions offer growth opportunities.

Mitotane is expected to witness a steady rise in global demand, driven by its effectiveness in treating rare medical conditions such as Cushing’s syndrome and adrenal cortical carcinoma (ACC).

In 2022, North America dominated the global mitotane drug market primarily due to its well-established healthcare infrastructure, extensive research capabilities, and proactive disease management initiatives. Moreover, the region has a high prevalence of adrenocortical carcinoma (ACC), the primary indication for mitotane treatment, and this prevalence is further driven by factors such as genetic predispositions and lifestyle-related risk factors. The strong regional pharmaceutical industry, regulatory support, and access to advanced diagnostics contribute to the widespread availability and utilization of mitotane as a standard of care for ACC patients. These factors collectively position North America as the leading market for mitotane drug usage and research, driving its dominance in the global market.

Over the projection period, Asia Pacific is expected to be the fastest-growing region in the global mitotane drug market. This growth is attributed to changing demographics, increasing healthcare investments, improving access to healthcare services, and rising awareness of rare conditions like adrenocortical carcinoma (ACC). Pharmaceutical companies are strategically expanding their presence in the Asia Pacific, conducting clinical trials, and customizing marketing approaches to meet the growing demand for mitotane and other critical treatments, making it a potential growth hotspot in the global market.

Key Highlights of the Report

The global mitotane drug market is segmented by formulation, indication, distribution channel, treatment phase, patient age group, and region. Injectable formulations are expected to exhibit substantial growth, while oral tablets/capsules currently dominate the market. Mitotane plays a pivotal role in the treatment of Cushing’s syndrome and adrenal cortical carcinoma (ACC). These indications continue to drive its market presence. Hospital pharmacies are the primary distribution channel for mitotane drugs, ensuring their availability for both inpatient and outpatient treatments. Retail pharmacies serve as an additional distribution point. Adjuvant therapy is a crucial category, with mitotane being used to prevent cancer recurrence after surgery. The segment addressing advanced or metastatic disease is expected to grow rapidly. The adult patient age group is projected to exhibit the highest growth, reflecting increased usage of mitotane for various indications in adult populations. The pediatric segment currently holds a substantial share.

The global mitotane drug market is primarily driven by several key factors, including its crucial role in treating rare medical conditions like Cushing’s syndrome and adrenal cortical carcinoma. Ongoing research into mitotane’s applications, including its potential in emerging indications, is likely to expand its market broader presence. Moreover, advancements in formulation techniques may lead to improved drug delivery methods, enhancing patient compliance and treatment outcomes. However, the market also faces challenges, such as the complex dosing and potential side effects associated with mitotane, which necessitate ongoing efforts in optimizing treatment protocols.

North America stands out as a dominant global market leader in the mitotane drug sector, propelled by its advanced healthcare infrastructure, extensive research capabilities, and a high prevalence of medical conditions necessitating mitotane treatment, notably Cushing’s syndrome and adrenal cortical carcinoma. Meanwhile, the Asia Pacific region presents substantial growth potential, owing to a rising prevalence of conditions necessitating mitotane treatment, driven by changing demographics and an increase in lifestyle-related risk factors.

What Are The Main Drivers Of The Global Mitotane Drug Market?

The primary drivers of the global mitotane drug market are the increasing incidence of adrenal cancer, particularly among the elderly population, and the growing adoption of targeted therapies in the field of oncology. As adrenal cancer remains a rare and challenging condition to treat, mitotane’s role as a key adjuvant therapy has gained prominence. Moreover, the broader trend toward personalized medicine and the exploration of mitotane’s potential applications in combination therapies for various cancer types further fuel its market growth. Efforts by pharmaceutical companies to expand research and development activities to enhance mitotane’s efficacy and safety profile also contribute to the market’s positive trajectory.

What Are The Major Challenges Faced By The Global Mitotane Drug Market?

The major challenges faced by the global mitotane drug market include limited awareness about mitotane and its therapeutic benefits among healthcare professionals and patients, which can hinder its adoption as a treatment option. Besides, the high cost of treatment and potential adverse effects associated with mitotane may pose pricing and reimbursement challenges, potentially limiting patient access. The rare nature of adrenal cancer further complicates clinical trial recruitment and research efforts, potentially slowing down the development of new mitotane-based therapies and treatment regimens.

What Are The Growth Opportunities In The Global Mitotane Drug Market?

The global mitotane drug market presents growth opportunities through the exploration of its potential applications beyond adrenal cancer, particularly in combination therapies and rare cancer types, offering avenues for expanded treatment options. In addition, tapping into emerging markets with increasing healthcare infrastructure and unmet medical needs can provide untapped revenue potential for mitotane drug manufacturers. Investments in R&D for novel formulations and drug delivery technologies, as well as strategic collaborations and regulatory approvals, can further strengthen the market’s growth prospects. Moreover, patient advocacy groups and support organizations play a pivotal role in raising awareness about adrenal cancer and advocating for improved access to mitotane therapies, enhancing the market’s reach and impact.

Market Drivers

Several factors drive the global mitotane drug market. The following are the key drivers of the global mitotane drug market:

Emerging Incidence of Adrenocortical Carcinoma (ACC)

One of the primary drivers fueling the global mitotane drug market growth is the growing incidence of adrenocortical carcinoma (ACC). ACC is a rare and aggressive cancer that develops in the adrenal cortex, and it accounts for only a small fraction of all cancer diagnoses. However, in recent years, there has been a noticeable increase in the number of ACC cases diagnosed worldwide. This rise in incidence can be attributed to several factors, including improved diagnostic techniques, increased awareness among healthcare providers, and advances in genetic testing. As more ACC cases are identified, there is a higher demand for effective treatments, and mitotane stands out as a standard therapy for this rare cancer. Its role in adjuvant therapy and palliative care positions it as a crucial treatment option for ACC patients, contributing to the growth of the mitotane drug industry.

Market Restraints

The global mitotane drug market faces challenges that may hinder its growth. These include the following:

Limited Indications and Niche Market

One of the major restraints affecting the global mitotane drug market growth is its limited indications and the niche market it serves. Mitotane is primarily used in the treatment of adrenocortical carcinoma (ACC), a rare and aggressive cancer originating in the adrenal cortex. ACC accounts for only a small fraction of all cancer cases globally, making it a niche condition. Due to this rarity, the patient pool requiring mitotane is relatively small. Pharmaceutical companies face challenges in investing resources and conducting extensive clinical trials for such a limited market, which can impact the overall availability and accessibility of mitotane. Moreover, the niche nature of the market means that the potential for revenue generation may be limited compared to drugs targeting more common diseases.

Opportunities

The global mitotane drug market offers significant growth opportunities. These include the following:

Orphan Drug Exclusivity and Market Expansion

Mitotane’s orphan drug status provides a unique opportunity for pharmaceutical companies. This designation grants extended market exclusivity periods, reducing the risk of generic competition and providing a favorable regulatory environment for mitotane. As a result, pharmaceutical companies are incentivized to invest in the development, production, and marketing of mitotane. This, in turn, ensures a stable supply of the drug and maintains its affordability for patients with ACC. Additionally, as research and clinical trials advance, mitotane’s potential use may expand beyond ACC. It also finds applications in the treatment of other rare cancers or conditions, further broadening its market reach and revenue potential. Exploring new indications for mitotane within the orphan drug framework offers a promising avenue for growth in the global mitotane drug market.

Competitive Landscape

Key Players

The global mitotane drug market features a handful of key pharmaceutical companies that manufacture and distribute mitotane for the treatment of adrenocortical carcinoma. The following are some of the top market players and their market shares:

HRA Pharma Rare Diseases
Bristol-Myers Squibb Company
TherDose Pharma Pvt. Ltd
Hikma Pharmaceuticals
Tizig Pharma Pvt. Ltd
Aspen Pharmacare
Prime Therapeutics
Novartis Pharmaceuticals Corporation
Others

These companies play a key role in ensuring the availability and accessibility of this essential treatment. They also engage in research & development activities related to mitotane, focusing on optimizing its efficacy, improving patient outcomes, and reducing side effects. Mitotane has a relatively limited number of competitors in the global market due to its orphan drug status and niche application in the treatment of adrenocortical carcinoma. The development and entry of new mitotane products into the market can be challenging due to regulatory hurdles and the need for extensive clinical trials. Existing manufacturers benefit from established regulatory approvals and market presence. Furthermore, companies are forming commercial alliances for the sale and distribution of mitotane.

In October 2020, AllianceRx Walgreens Prime, one of the largest specialty & home delivery pharmacies in the United States, was designated the exclusive specialty pharmacy and clinical support distributor for two of HRA Pharma Rare Diseases’ rare illness drugs, Lysodren and Metopirone. Lysodren (mitotane) is the only FDA-approved drug for addressing adrenocortical carcinoma, a rare form of cancer of the adrenal glands. Metopirone (metyrapone) is a prescription medication used to treat adrenocorticotropic hormone (ACTH) deficiencies and ACTH-dependent Cushing’s syndrome. ACTH is a hormone produced by the pituitary gland in the brain.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The global mitotane drug market is expected to continue growing, driven by the rising incidence of adrenocortical carcinoma and ongoing research efforts to optimize its use in cancer treatment.
Market segmented by formulation, indication, distribution channel, treatment phase, patient age group, and region.
Mitotane’s market is primarily segmented by formulation, with injectable formulations showing high growth potential due to their effectiveness, while oral tablets/capsules currently dominate the global market.
In terms of indication, mitotane plays a crucial role in treating Cushing’s syndrome and remains dominant in the treatment of adrenal cortical carcinoma (ACC).
Mitotane primarily serves as an adjuvant therapy for advanced adrenal cancer patients.
Despite its effectiveness, mitotane is associated with various side effects, including gastrointestinal issues, neurological symptoms, and adrenal insufficiency.
Mitotane has a limited number of competitors, and it is considered the standard treatment for adrenocortical carcinoma. Its orphan drug status provides certain advantages, such as extended exclusivity periods, encouraging pharmaceutical companies to invest in its development.

Future Outlook

Improved patient management strategies and potential advancements in drug formulation further shape its future market dynamics.
Ongoing research into mitotane’s applications, including its potential in emerging indications, is likely to expand its market presence in the coming years.
Increasing concern among healthcare professionals and patients about the benefits of mitotane in managing hormonal disorders and certain cancers is expected to boost its adoption.
Mitotane’s role in pediatric patient care is likely to gain more attention, potentially leading to pediatric-specific formulations and treatment guidelines.

Segmentation

By Formulation
- Oral Tablets/Capsules
- Injectable Formulations
By Indication
- Adrenal Cortical Carcinoma (ACC)
- Cushing’s Syndrome
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
By Treatment Phase
- Adjuvant Therapy
- Advanced or Metastatic Disease
By Patient Age Group
- Pediatric
- Adult
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

In the mitotane drug market, several adjacent markets have high revenue growth opportunities. The key adjacent markets for the mitotane drug market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Mitotane Drug Market

2.1.1. Global Mitotane Drug Market, By Formulation

2.1.2. Global Mitotane Drug Market, By Indication

2.1.3. Global Mitotane Drug Market, By Distribution Channel

2.1.4. Global Mitotane Drug Market, By Treatment Phase

2.1.5. Global Mitotane Drug Market, By Patient Age Group

2.1.6. Global Mitotane Drug Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Mitotane Drug Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Mitotane Drug Market Drivers

3.2.2. Mitotane Drug Market Restraints

3.2.3. Mitotane Drug Market Opportunities

3.2.4. Major Mitotane Drug Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Formulation

3.5.2. Indication

3.5.3. Distribution Channel

3.5.4. Treatment Phase

3.5.5. Patient Age Group

3.5.6. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Mitotane Drug Market: Company Market Share, Value 2022

4.1.2. Global Mitotane Drug Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Mitotane Drug Market: Top 3 Company Market Share, Value 2022

4.2. Global Mitotane Drug Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Mitotane Drug Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Mitotane Drug Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Mitotane Drug Market, By Formulation

8.1. Global Mitotane Drug Market Overview, by Formulation

8.1.1. Global Mitotane Drug Market Revenue Share, By Formulation, 2022 Vs 2030 (in %)

8.2. Oral Tablets/Capsules

8.2.1. Global Mitotane Drug Market, By Oral Tablets/Capsules, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Oral Tablets/Capsules

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Injectable Formulations

8.3.1. Global Mitotane Drug Market, By Injectable Formulations, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Injectable Formulations

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

9. Global Mitotane Drug Market, By Indication

9.1. Global Mitotane Drug Market Overview, by Indication

9.1.1. Global Mitotane Drug Market Revenue Share, By Indication, 2022 Vs 2030 (in %)

9.2. Adrenal Cortical Carcinoma (ACC)

9.2.1. Global Mitotane Drug Market, By Adrenal Cortical Carcinoma (ACC), By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Adrenal Cortical Carcinoma (ACC)

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Cushing’s Syndrome

9.3.1. Global Mitotane Drug Market, By Cushing’s Syndrome, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Cushing’s Syndrome

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

10. Global Mitotane Drug Market, By Distribution Channel

10.1. Global Mitotane Drug Market Overview, by Distribution Channel

10.1.1. Global Mitotane Drug Market Revenue Share, By Distribution Channel, 2022 Vs 2030 (in %)

10.2. Hospital Pharmacies

10.2.1. Global Mitotane Drug Market, By Hospital Pharmacies, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Hospital Pharmacies

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Retail Pharmacies

10.3.1. Global Mitotane Drug Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Retail Pharmacies

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

11. Global Mitotane Drug Market, By Treatment Phase

11.1. Global Mitotane Drug Market Overview, by Treatment Phase

11.1.1. Global Mitotane Drug Market Revenue Share, By Treatment Phase, 2022 Vs 2030 (in %)

11.2. Adjuvant Therapy

11.2.1. Global Mitotane Drug Market, By Adjuvant Therapy, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Adjuvant Therapy

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Advanced or Metastatic Disease

11.3.1. Global Mitotane Drug Market, By Advanced or Metastatic Disease, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Advanced or Metastatic Disease

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

12. Global Mitotane Drug Market, By Patient Age Group

12.1. Global Mitotane Drug Market Overview, by Patient Age Group

12.1.1. Global Mitotane Drug Market Revenue Share, By Patient Age Group, 2022 Vs 2030 (in %)

12.2. Pediatric

12.2.1. Global Mitotane Drug Market, By Pediatric, By Region, 2017-2030 (US$ Mn)

12.2.2. Market Dynamics for Pediatric

12.2.2.1. Drivers

12.2.2.2. Restraints

12.2.2.3. Opportunities

12.2.2.4. Trends

12.3. Adult

12.3.1. Global Mitotane Drug Market, By Adult, By Region, 2017-2030 (US$ Mn)

12.3.2. Market Dynamics for Adult

12.3.2.1. Drivers

12.3.2.2. Restraints

12.3.2.3. Opportunities

12.3.2.4. Trends

13. Global Mitotane Drug Market, By Region

13.1. Global Mitotane Drug Market Overview, by Region

13.1.1. Global Mitotane Drug Market, By Region, 2022 vs 2030 (in%)

13.2. Formulation

13.2.1. Global Mitotane Drug Market, By Formulation, 2017-2030 (US$ Mn)

13.3. Indication

13.3.1. Global Mitotane Drug Market, By Indication, 2017-2030 (US$ Mn)

13.4. Distribution Channel

13.4.1. Global Mitotane Drug Market, By Distribution Channel, 2017-2030 (US$ Mn)

13.5. Treatment Phase

13.5.1. Global Mitotane Drug Market, By Treatment Phase, 2017-2030 (US$ Mn)

13.6. Patient Age Group

13.6.1. Global Mitotane Drug Market, By Patient Age Group, 2017-2030 (US$ Mn)

14. North America Mitotane Drug Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. North America Mitotane Drug Market, by Formulation, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. North America Mitotane Drug Market, by Indication, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. North America Mitotane Drug Market, by Distribution Channel, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. North America Mitotane Drug Market, by Treatment Phase, 2017-2030(US$ Mn)

14.5.1. Overview

14.5.2. SRC Analysis

14.6. North America Mitotane Drug Market, by Patient Age Group, 2017-2030(US$ Mn)

14.6.1. Overview

14.6.2. SRC Analysis

14.7. North America Mitotane Drug Market, by Country, 2017-2030 (US$ Mn)

14.7.1. North America Mitotane Drug Market, by Country, 2022 Vs 2030 (in%)

14.7.2. U.S.

14.7.3. Canada

14.7.4. Mexico

15. Europe Mitotane Drug Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Europe Mitotane Drug Market, by Formulation, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Europe Mitotane Drug Market, by Indication, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Europe Mitotane Drug Market, by Distribution Channel, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Europe Mitotane Drug Market, by Treatment Phase, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. Europe Mitotane Drug Market, by Patient Age Group, 2017-2030(US$ Mn)

15.6.1. Overview

15.6.2. SRC Analysis

15.7. Europe Mitotane Drug Market, by Country, 2017-2030 (US$ Mn)

15.7.1. Europe Mitotane Drug Market, by Country, 2022 Vs 2030 (in%)

15.7.2. UK

15.7.3. France

15.7.4. Germany

15.7.5. Italy

15.7.6. Spain

15.7.7. Benelux

15.7.8. Russia

15.7.9. Rest of Europe

16. Asia Pacific Mitotane Drug Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Asia Pacific Mitotane Drug Market, by Formulation, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Asia Pacific Mitotane Drug Market, by Indication, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Asia Pacific Mitotane Drug Market, by Distribution Channel, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Asia Pacific Mitotane Drug Market, by Treatment Phase, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Asia Pacific Mitotane Drug Market, by Patient Age Group, 2017-2030(US$ Mn)

16.6.1. Overview

16.6.2. SRC Analysis

16.7. Asia Pacific Mitotane Drug Market, by Country, 2017-2030 (US$ Mn)

16.7.1. Asia Pacific Mitotane Drug Market, by Country, 2022 Vs 2030 (in%)

16.7.2. China

16.7.3. Japan

16.7.4. India

16.7.5. South Korea

16.7.6. South East Asia

16.7.7. Rest of Asia Pacific

17. Latin America Mitotane Drug Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Latin America Mitotane Drug Market, by Formulation, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Latin America Mitotane Drug Market, by Indication, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Latin America Mitotane Drug Market, by Distribution Channel, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Latin America Mitotane Drug Market, by Treatment Phase, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Latin America Mitotane Drug Market, by Patient Age Group, 2017-2030(US$ Mn)

17.6.1. Overview

17.6.2. SRC Analysis

17.7. Latin America Mitotane Drug Market, by Country, 2017-2030 (US$ Mn)

17.7.1. Latin America Mitotane Drug Market, by Country, 2022 Vs 2030 (in%)

17.7.2. Brazil

17.7.3. Argentina

17.7.4. Rest of Latin America

18. Middle East Mitotane Drug Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Middle East Mitotane Drug Market, by Formulation, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Middle East Mitotane Drug Market, by Indication, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Middle East Mitotane Drug Market, by Distribution Channel, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Middle East Mitotane Drug Market, by Treatment Phase, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Middle East Mitotane Drug Market, by Patient Age Group, 2017-2030(US$ Mn)

18.6.1. Overview

18.6.2. SRC Analysis

18.7. Middle East Mitotane Drug Market, by Country, 2017-2030 (US$ Mn)

18.7.1. Middle East Mitotane Drug Market, by Country, 2022 Vs 2030 (in%)

18.7.2. UAE

18.7.3. Saudi Arabia

18.7.4. Rest of Middle East

19. Africa Mitotane Drug Market Analysis

19.1. Overview

19.1.1. Market Dynamics for North America

19.1.1.1. Drivers

19.1.1.2. Restraints

19.1.1.3. Opportunities

19.1.1.4. Trends

19.2. Africa Mitotane Drug Market, by Formulation, 2017-2030(US$ Mn)

19.2.1. Overview

19.2.2. SRC Analysis

19.3. Africa Mitotane Drug Market, by Indication, 2017-2030(US$ Mn)

19.3.1. Overview

19.3.2. SRC Analysis

19.4. Africa Mitotane Drug Market, by Distribution Channel, 2017-2030(US$ Mn)

19.4.1. Overview

19.4.2. SRC Analysis

19.5. Africa Mitotane Drug Market, by Treatment Phase, 2017-2030(US$ Mn)

19.5.1. Overview

19.5.2. SRC Analysis

19.6. Africa Mitotane Drug Market, by Patient Age Group, 2017-2030(US$ Mn)

19.6.1. Overview

19.6.2. SRC Analysis

19.7. Africa Mitotane Drug Market, by Country, 2017-2030 (US$ Mn)

19.7.1. Middle East Mitotane Drug Market, by Country, 2022 Vs 2030 (in%)

19.7.2. South Africa

19.7.3. Egypt

19.7.4. Rest of Africa

20. Company Profiles

20.1. HRA Pharma Rare Diseases

20.1.1. Company Overview

20.1.2. Products/Services Portfolio

20.1.3. Geographical Presence

20.1.4. SWOT Analysis

20.1.5. Financial Summary

20.1.5.1. Market Revenue and Net Profit (2019-2022)

20.1.5.2. Business Segment Revenue Analysis

20.1.5.3. Geographical Revenue Analysis

20.2. Bristol-Myers Squibb Company

20.3. TherDose Pharma Pvt. Ltd

20.4. Hikma Pharmaceuticals

20.5. Tizig Pharma Pvt. Ltd

20.6. Aspen Pharmacare

20.7. Prime Therapeutics

20.8. Novartis Pharmaceuticals Corporation

20.9. Others

21. Research Methodology

21.1. Research Methodology

21.2. Phase I – Secondary Research

21.3. Phase II – Data Modelling

21.3.1. Company Share Analysis Model

21.3.2. Revenue Based Modelling

21.4. Phase III – Primary Research

21.5. Research Limitations

21.5.1. Assumptions

List of Figures

FIG. 1 Global Mitotane Drug Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Mitotane Drug Market Segmentation

FIG. 4 Global Mitotane Drug Market, by Formulation, 2022 (US$ Mn)

FIG. 5 Global Mitotane Drug Market, by Indication, 2022 (US$ Mn)

FIG. 6 Global Mitotane Drug Market, by Distribution Channel, 2022 (US$ Mn)

FIG. 7 Global Mitotane Drug Market, by Treatment Phase, 2022 (US$ Mn)

FIG. 8 Global Mitotane Drug Market, by Patient Age Group, 2022 (US$ Mn)

FIG. 9 Global Mitotane Drug Market, by Geography, 2022 (US$ Mn)

FIG. 10 Attractive Investment Proposition, by Formulation, 2022

FIG. 11 Attractive Investment Proposition, by Indication, 2022

FIG. 12 Attractive Investment Proposition, by Distribution Channel, 2022

FIG. 13 Attractive Investment Proposition, by Treatment Phase, 2022

FIG. 14 Attractive Investment Proposition, by Patient Age Group, 2022

FIG. 15 Attractive Investment Proposition, by Geography, 2022

FIG. 16 Global Market Share Analysis of Key Mitotane Drug Market Manufacturers, 2022

FIG. 17 Global Market Positioning of Key Mitotane Drug Market Manufacturers, 2022

FIG. 18 Global Mitotane Drug Market Value Contribution, By Formulation, 2022 & 2030 (Value %)

FIG. 19 Global Mitotane Drug Market, by Oral Tablets/Capsules, Value, 2017-2030 (US$ Mn)

FIG. 20 Global Mitotane Drug Market, by Injectable Formulations, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Mitotane Drug Market Value Contribution, By Indication, 2022 & 2030 (Value %)

FIG. 22 Global Mitotane Drug Market, by Adrenal Cortical Carcinoma (ACC), Value, 2017-2030 (US$ Mn)

FIG. 23 Global Mitotane Drug Market, by Cushing’s Syndrome, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Mitotane Drug Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)

FIG. 25 Global Mitotane Drug Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Mitotane Drug Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Mitotane Drug Market Value Contribution, By Treatment Phase, 2022 & 2030 (Value %)

FIG. 28 Global Mitotane Drug Market, by Adjuvant Therapy, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Mitotane Drug Market, by Advanced or Metastatic Disease, Value, 2017-2030 (US$ Mn)

FIG. 30 Global Mitotane Drug Market Value Contribution, By Patient Age Group, 2022 & 2030 (Value %)

FIG. 31 Global Mitotane Drug Market, by Pediatric, Value, 2017-2030 (US$ Mn)

FIG. 32 Global Mitotane Drug Market, by Adult, Value, 2017-2030 (US$ Mn)

FIG. 33 North America Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 34 U.S. Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 35 Canada Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 36 Mexico Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 37 Europe Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 38 Germany Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 39 France Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 40 U.K. Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 41 Italy Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 42 Spain Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 43 Benelux Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 44 Russia Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 45 Rest of Europe Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 46 Asia Pacific Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 47 China Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 48 Japan Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 49 India Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 50 South Korea Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 51 South-East Asia Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 52 Rest of Asia Pacific Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 53 Latin America Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 54 Brazil Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 55 Argentina Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 56 Rest of Latin America Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 57 Middle East Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 58 UAE Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 59 Saudi Arabia Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 60 Rest of Middle East Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 61 Africa Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 62 South Africa Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 63 Egypt Mitotane Drug Market, 2017-2030 (US$ Mn)

FIG. 64 Rest of Africa Mitotane Drug Market, 2017-2030 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Mitotane Drug Market

TABLE 2 Global Mitotane Drug Market: Market Drivers Impact Analysis

TABLE 3 Global Mitotane Drug Market: Market Restraints Impact Analysis

TABLE 4 Global Mitotane Drug Market, by Competitive Benchmarking, 2022

TABLE 5 Global Mitotane Drug Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Mitotane Drug Market, by Key Strategies Analysis, 2022

TABLE 7 Global Mitotane Drug Market, by Oral Tablets/Capsules, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Mitotane Drug Market, by Oral Tablets/Capsules, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Mitotane Drug Market, by Injectable Formulations, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Mitotane Drug Market, by Injectable Formulations, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Mitotane Drug Market, by Adrenal Cortical Carcinoma (ACC), By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Mitotane Drug Market, by Adrenal Cortical Carcinoma (ACC), By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Mitotane Drug Market, by Cushing’s Syndrome, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Mitotane Drug Market, by Cushing’s Syndrome, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Mitotane Drug Market, by Hospital Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Mitotane Drug Market, by Hospital Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Mitotane Drug Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Mitotane Drug Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Mitotane Drug Market, by Adjuvant Therapy, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Mitotane Drug Market, by Adjuvant Therapy, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Mitotane Drug Market, by Advanced or Metastatic Disease, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Mitotane Drug Market, by Advanced or Metastatic Disease, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Mitotane Drug Market, by Pediatric, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Mitotane Drug Market, by Pediatric, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Mitotane Drug Market, by Adult, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Mitotane Drug Market, by Adult, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 28 Global Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 29 Global Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 30 Global Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 31 Global Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 32 Global Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 33 Global Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 34 Global Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 35 Global Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 36 Global Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 37 Global Mitotane Drug Market, by Region, 2017-2022 (US$ Mn)

TABLE 38 Global Mitotane Drug Market, by Region, 2023-2030 (US$ Mn)

TABLE 39 North America Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 40 North America Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 41 North America Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 42 North America Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 43 North America Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 44 North America Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 45 North America Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 46 North America Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 47 North America Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 48 North America Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 49 North America Mitotane Drug Market, by Country, 2017-2022 (US$ Mn)

TABLE 50 North America Mitotane Drug Market, by Country, 2023-2030 (US$ Mn)

TABLE 51 United States Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 52 United States Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 53 United States Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 54 United States Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 55 United States Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 56 United States Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 57 United States Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 58 United States Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 59 United States Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 60 United States Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 61 Canada Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 62 Canada Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 63 Canada Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 64 Canada Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 65 Canada Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 66 Canada Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 67 Canada Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 68 Canada Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 69 Canada Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 70 Canada Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 71 Mexico Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 72 Mexico Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 73 Mexico Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 74 Mexico Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 75 Mexico Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 76 Mexico Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 77 Mexico Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 78 Mexico Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 79 Mexico Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 80 Mexico Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 81 Europe Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 82 Europe Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 83 Europe Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 84 Europe Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 85 Europe Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 86 Europe Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 87 Europe Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 88 Europe Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 89 Europe Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 90 Europe Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 91 Europe Mitotane Drug Market, by Country, 2017-2022 (US$ Mn)

TABLE 92 Europe Mitotane Drug Market, by Country, 2023-2030 (US$ Mn)

TABLE 93 Germany Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 94 Germany Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 95 Germany Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 96 Germany Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 97 Germany Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 98 Germany Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 99 Germany Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 100 Germany Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 101 Germany Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 102 Germany Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 103 France Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 104 France Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 105 France Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 106 France Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 107 France Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 108 France Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 109 France Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 110 France Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 111 France Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 112 France Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 113 United Kingdom Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 114 United Kingdom Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 115 United Kingdom Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 116 United Kingdom Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 117 United Kingdom Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 118 United Kingdom Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 119 United Kingdom Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 120 United Kingdom Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 121 United Kingdom Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 122 United Kingdom Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 123 Italy Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 124 Italy Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 125 Italy Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 126 Italy Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 127 Italy Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 128 Italy Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 129 Italy Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 130 Italy Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 131 Italy Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 132 Italy Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 133 Spain Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 134 Spain Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 135 Spain Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 136 Spain Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 137 Spain Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 138 Spain Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 139 Spain Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 140 Spain Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 141 Spain Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 142 Spain Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 143 Benelux Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 144 Benelux Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 145 Benelux Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 146 Benelux Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 147 Benelux Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 148 Benelux Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 149 Benelux Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 150 Benelux Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 151 Benelux Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 152 Benelux Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 153 Russia Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 154 Russia Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 155 Russia Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 156 Russia Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 157 Russia Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 158 Russia Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 159 Russia Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 160 Russia Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 161 Russia Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 162 Russia Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 163 Rest of Europe Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 164 Rest of Europe Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 165 Rest of Europe Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 166 Rest of Europe Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 167 Rest of Europe Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 168 Rest of Europe Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 169 Rest of Europe Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 170 Rest of Europe Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 171 Rest of Europe Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 172 Rest of Europe Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 173 Asia Pacific Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 174 Asia Pacific Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 175 Asia Pacific Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 176 Asia Pacific Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 177 Asia Pacific Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 178 Asia Pacific Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 179 Asia Pacific Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 180 Asia Pacific Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 181 Asia Pacific Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 182 Asia Pacific Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 183 China Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 184 China Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 185 China Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 186 China Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 187 China Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 188 China Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 189 China Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 190 China Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 191 China Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 192 China Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 193 Japan Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 194 Japan Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 195 Japan Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 196 Japan Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 197 Japan Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 198 Japan Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 199 Japan Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 200 Japan Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 201 Japan Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 202 Japan Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 203 India Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 204 India Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 205 India Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 206 India Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 207 India Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 208 India Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 209 India Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 210 India Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 211 India Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 212 India Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 213 South Korea Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 214 South Korea Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 215 South Korea Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 216 South Korea Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 217 South Korea Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 218 South Korea Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 219 South Korea Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 220 South Korea Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 221 South Korea Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 222 South Korea Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 223 South-East Asia Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 224 South-East Asia Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 225 South-East Asia Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 226 South-East Asia Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 227 South-East Asia Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 228 South-East Asia Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 229 South-East Asia Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 230 South-East Asia Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 231 South-East Asia Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 232 South-East Asia Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 233 Rest of Asia Pacific Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 234 Rest of Asia Pacific Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 235 Rest of Asia Pacific Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 236 Rest of Asia Pacific Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 237 Rest of Asia Pacific Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 238 Rest of Asia Pacific Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 239 Rest of Asia Pacific Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 240 Rest of Asia Pacific Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 241 Rest of Asia Pacific Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 242 Rest of Asia Pacific Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 243 Latin America Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 244 Latin America Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 245 Latin America Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 246 Latin America Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 247 Latin America Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 248 Latin America Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 249 Latin America Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 250 Latin America Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 251 Latin America Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 252 Latin America Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 253 Brazil Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 254 Brazil Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 255 Brazil Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 256 Brazil Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 257 Brazil Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 258 Brazil Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 259 Brazil Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 260 Brazil Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 261 Brazil Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 262 Brazil Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 263 Argentina Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 264 Argentina Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 265 Argentina Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 266 Argentina Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 267 Argentina Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 268 Argentina Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 269 Argentina Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 270 Argentina Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 271 Argentina Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 272 Argentina Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 273 Rest of Latin America Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 274 Rest of Latin America Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 275 Rest of Latin America Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 276 Rest of Latin America Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 277 Rest of Latin America Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 278 Rest of Latin America Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 279 Rest of Latin America Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 280 Rest of Latin America Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 281 Rest of Latin America Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 282 Rest of Latin America Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 283 Middle East Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 284 Middle East Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 285 Middle East Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 286 Middle East Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 287 Middle East Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 288 Middle East Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 289 Middle East Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 290 Middle East Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 291 Middle East Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 292 Middle East Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 293 UAE Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 294 UAE Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 295 UAE Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 296 UAE Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 297 UAE Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 298 UAE Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 299 UAE Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 300 UAE Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 301 UAE Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 302 UAE Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 303 Saudi Arabia Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 304 Saudi Arabia Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 305 Saudi Arabia Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 306 Saudi Arabia Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 307 Saudi Arabia Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 308 Saudi Arabia Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 309 Saudi Arabia Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 310 Saudi Arabia Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 311 Saudi Arabia Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 312 Saudi Arabia Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 313 Rest of Middle East Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 314 Rest of Middle East Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 315 Rest of Middle East Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 316 Rest of Middle East Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 317 Rest of Middle East Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 318 Rest of Middle East Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 319 Rest of Middle East Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 320 Rest of Middle East Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 321 Rest of Middle East Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 322 Rest of Middle East Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 323 Africa Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 324 Africa Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 325 Africa Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 326 Africa Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 327 Africa Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 328 Africa Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 329 Africa Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 330 Africa Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 331 Africa Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 332 Africa Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 333 South Africa Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 334 South Africa Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 335 South Africa Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 336 South Africa Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 337 South Africa Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 338 South Africa Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 339 South Africa Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 340 South Africa Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 341 South Africa Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 342 South Africa Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 343 Egypt Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 344 Egypt Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 345 Egypt Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 346 Egypt Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 347 Egypt Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 348 Egypt Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 349 Egypt Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 350 Egypt Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 351 Egypt Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 352 Egypt Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

TABLE 353 Rest of Africa Mitotane Drug Market, by Formulation, 2017-2022 (US$ Mn)

TABLE 354 Rest of Africa Mitotane Drug Market, by Formulation, 2023-2030 (US$ Mn)

TABLE 355 Rest of Africa Mitotane Drug Market, by Indication, 2017-2022 (US$ Mn)

TABLE 356 Rest of Africa Mitotane Drug Market, by Indication, 2023-2030 (US$ Mn)

TABLE 357 Rest of Africa Mitotane Drug Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 358 Rest of Africa Mitotane Drug Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 359 Rest of Africa Mitotane Drug Market, by Treatment Phase, 2017-2022 (US$ Mn)

TABLE 360 Rest of Africa Mitotane Drug Market, by Treatment Phase, 2023-2030 (US$ Mn)

TABLE 361 Rest of Africa Mitotane Drug Market, by Patient Age Group, 2017-2022 (US$ Mn)

TABLE 362 Rest of Africa Mitotane Drug Market, by Patient Age Group, 2023-2030 (US$ Mn)

Frequently asked questions

What is the current size of the global mitotane drug market?

The global mitotane drug market was valued at USD 17.5 Million in 2022.

What is the expected growth rate of the mitotane drug market between 2023 and 2030?

The mitotane drug market is expected to grow at a CAGR of 4.8% between 2023 and 2030, reaching USD 25.46 Million in 2030.

Which segment is leading the market share in terms of formulation?

Oral tablets/capsules are the leading segment by formulation, holding over 65% share in value in 2022.

Which indication segment governs the demand for mitotane drugs in the world?

The adrenal cortical carcinoma (ACC) segment governs the global demand for mitotane drugs, holding a massive share of over 54% in 2022.

Which treatment phase segment will post the highest CAGR in the forecast period?

The advanced or metastatic disease segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the mitotane drug industry?

With more than one-third of the market in 2022, North America is driving the expansion of the mitotane drug industry.

Who are the major players in the global mitotane drug market?

The top players include HRA Pharma Rare Diseases, Bristol-Myers Squibb Company, TherDose Pharma Pvt. Ltd, Hikma Pharmaceuticals, Tizig Pharma Pvt. Ltd, Aspen Pharmacare, Prime Therapeutics, Novartis Pharmaceuticals Corporation, and Others.

What are the major market drivers of the mitotane drug industry?

The major market drivers of the mitotane drug industry include the increasing incidence of adrenocortical carcinoma (ACC) and the orphan drug status with regulatory support.

What are the major market restraints of the mitotane drug industry?

The major market restraints of the mitotane drug industry encompass its limited indications and niche market, as well as the significant side effects and tolerability challenges associated with mitotane treatment.

What are the major market opportunities of the mitotane drug industry?

The major market opportunities of the mitotane drug industry lie in exploring combination therapies to enhance treatment efficacy and leveraging orphan drug exclusivity for potential market expansion into new indications.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –